Clinical Trial Search Results

386 studies were found about ( Viread OR tenofovir disoproxil fumarate )
Filter Results: All Studies Studies seeking new volunteers Studies with results

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Condition: HIV-1 Infections; HIV Infections

NCT ID: NCT00557245

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01780506

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01797445

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

Condition: Acute HIV Infection; HIV Infections

NCT ID: NCT00924898

Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01108510

Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00078182

Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients

Condition: HIV; HIV Infections

NCT ID: NCT00358696

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01705574

Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01497899

Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01565850

Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01475838

Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01495702

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01533259

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01721109

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Condition: HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1

NCT ID: NCT00540449

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT00869557

Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT01095796

Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00016588

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Condition: HIV Infections

NCT ID: NCT00808002

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT01106586

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

Condition: HIV Prevention; HIV Infections

NCT ID: NCT00984971

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00074581

HIV Persistence and Viral Reservoirs

Condition: HIV; HIV Infections

NCT ID: NCT01025427

Raltegravir Activity In Lymphoid Tissues

Condition: HIV Infection; HIV Infections

NCT ID: NCT00863668

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Condition: HIV; HIV Infections

NCT ID: NCT00928187

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

Condition: HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT00100048

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00007436

Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

Condition: HIV Infections

NCT ID: NCT00011089

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00002450

Part A: Drug Interaction Study of GS-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: Phase 2, Open-Label Study to Investigate Efficacy and Safety of GS-7977 for 12 Weeks in HIV/HCV Co-infected Patients.

Condition: Hepatitis C; HIV

NCT ID: NCT01565889

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Condition: HIV Infections

NCT ID: NCT00051831

Effectiveness of Nucleoside Supplementation and Substituting Tenofovir Disoproxil Fumarate for Other Drugs in Anti-HIV Regimens in Reversing Fat Loss in HIV Infected Adults

Condition: HIV Infections; Lipodystrophy; Metabolic Diseases; Nutrition Disorders

NCT ID: NCT00119379

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Condition: HIV Infections

NCT ID: NCT00122512

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00002415

Tenofovir Disoproxil Fumarate to Treat Pediatric HIV

Condition: HIV Infection

NCT ID: NCT00024986

Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

Condition: HIV Infections

NCT ID: NCT00441298

Botswana Tenofovir Oral HIV Prophylaxis Trial

Condition: HIV Infection

NCT ID: NCT00111150

Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

Condition: HIV Infections

NCT ID: NCT00352053

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Condition: HIV Infections

NCT ID: NCT00458393

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT00335322

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Condition: HIV Infections

NCT ID: NCT00122486

Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.

Condition: HIV Infections

NCT ID: NCT00158821

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

Condition: HIV Infections

NCT ID: NCT00002453

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

Condition: HIV Infection

NCT ID: NCT00038506

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Condition: HIV Infections

NCT ID: NCT01040091

Botswana TDF/FTC Oral HIV Prophylaxis Trial

Condition: HIV Infections

NCT ID: NCT00448669

Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women

Condition: HIV Infections

NCT ID: NCT00705679

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Condition: HIV Infections; Hepatitis B

NCT ID: NCT00127959

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01363011

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Condition: HIV Infections

NCT ID: NCT00528957

Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis

Condition: Tuberculosis; HIV Infections

NCT ID: NCT00474435

Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies

Condition: HIV Infections

NCT ID: NCT00120471

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

Condition: HIV Infections

NCT ID: NCT00076791

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

Condition: HIV Infection

NCT ID: NCT00244712

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

Condition: HIV Infections

NCT ID: NCT00106379

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

Condition: HIV Infections

NCT ID: NCT00654147

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

Condition: HIV Infections; Hepatitis B

NCT ID: NCT00662545

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Condition: HIV Infections; Tuberculosis

NCT ID: NCT00115609

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

Condition: HIV Infections

NCT ID: NCT00594373

Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Condition: Hepatitis B; HIV Infections

NCT ID: NCT00391638

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)

Condition: HIV Infection

NCT ID: NCT01533272

Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)

Condition: HIV Infections

NCT ID: NCT00573001

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men and in At-Risk Women

Condition: HIV Infection

NCT ID: NCT01505114

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1

Condition: HIV Infection

NCT ID: NCT01576731

Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00122577

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Condition: HIV Infections

NCT ID: NCT01066962

Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects

Condition: HIV Infections

NCT ID: NCT00350272

A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients

Condition: HIV Infections; Hepatitis B Virus

NCT ID: NCT00660361

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT00112047

KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

Condition: Infection, Human Immunodeficiency Virus I; HIV Infection

NCT ID: NCT00549198

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00002396

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

Condition: HIV Infections; Dyslipidemia; Hyperlipidemia; Hypercholesterolemia; Hypertriglyceridemia

NCT ID: NCT00109603

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Condition: Human Immunodeficiency Virus I Infection; HIV Infection

NCT ID: NCT00044577

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

Condition: HIV Infections

NCT ID: NCT00959894

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

Condition: HIV Infections

NCT ID: NCT00532168

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.

Condition: HIV-1 Infection

NCT ID: NCT01309243

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Condition: HIV Infections

NCT ID: NCT00528060

Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV-1 Infection

NCT ID: NCT00892437

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT00105079

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Condition: HIV Infections

NCT ID: NCT00028366

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

Condition: HIV Infection

NCT ID: NCT00053638

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

Condition: HIV Infection

NCT ID: NCT00234910

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Condition: HIV-1 Infections

NCT ID: NCT01033760

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Condition: HIV Infections

NCT ID: NCT00594646

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

Condition: HIV Infections

NCT ID: NCT00389207

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

Condition: HIV; Osteopenia; Osteoporosis; HIV Infections

NCT ID: NCT00939874

Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Condition: Chronic Hepatitis B; HIV Infections

NCT ID: NCT00221286

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Condition: HIV-2 Infection

NCT ID: NCT01605890

Tenofovir in HIV/HBV Coinfection

Condition: HIV Infection; Hepatitis B Coinfection

NCT ID: NCT00192595

Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

Condition: HIV Prevention

NCT ID: NCT01386294

A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

Condition: HIV Infections; Hepatitis B

NCT ID: NCT00033163

Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy

Condition: HIV Infections; Lipoatrophy

NCT ID: NCT00312832

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

Condition: HBV Coinfection; HIV Infections

NCT ID: NCT01318096

A Study to Compare Efficacy in Terms of Plasma Human Immunodeficiency Virus-Type 1 (HIV-1) Ribonucleic Acid (RNA) Between 2 Fixed Dose Combinations After a Switch in Fully Suppressed Patients

Condition: Human Immunodeficiency Virus-type 1 Infection

NCT ID: NCT01709084

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

Condition: HIV Infection

NCT ID: NCT00131677

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00038220

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

Condition: HIV Infections

NCT ID: NCT00035932

Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Condition: HIV Infection

NCT ID: NCT00158457

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

Condition: HIV Infections

NCT ID: NCT00490412

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Condition: HIV Infections

NCT ID: NCT00323544

Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria

Condition: HIV Infections; Proteinuria

NCT ID: NCT01044771

Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV

Condition: HIV; Hepatitis B

NCT ID: NCT01125696

Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00365612

Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00946595

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT01516970

PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers

Condition: HIV Infection; HIV Infections

NCT ID: NCT01108926

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01641809

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT00414518

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

Condition: HIV Infection; Hepatitis C

NCT ID: NCT00121017

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

Condition: HIV Infections

NCT ID: NCT00043966

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

Condition: HIV Infections; AIDS

NCT ID: NCT00302822

Raltegravir Switch for Toxicity or Adverse Events

Condition: HIV/AIDS; Antiretroviral Therapy; HIV Infections

NCT ID: NCT00958100

Renal, Endocrine, and Bone Changes in Response to TDF/FTC in Uninfected YMSM.

Condition: HIV Infection

NCT ID: NCT01769469

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875AM5)(COMPLETED)

Condition: HIV Infections

NCT ID: NCT00551018

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet

Condition: HIV

NCT ID: NCT01694420

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

Condition: HIV Infections

NCT ID: NCT00544128

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1

NCT ID: NCT01345630

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT01384734

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine

Condition: HIV Infection

NCT ID: NCT01159743

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Condition: HIV Infections

NCT ID: NCT00660972

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

Condition: HIV Infections

NCT ID: NCT00442962

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

Condition: Human Immunodeficiency Virus Infection

NCT ID: NCT01737359

Appropriate Timing of HAART in Co-infected HIV/TB Patients

Condition: HIV Infections; Tuberculosis

NCT ID: NCT01014481

Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

Condition: HIV Infections

NCT ID: NCT00087464

Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients

Condition: HIV Infections

NCT ID: NCT00647244

Bangkok Tenofovir Study

Condition: HIV Infections

NCT ID: NCT00119106

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT00827112

Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients

Condition: HIV Infections

NCT ID: NCT00356616

Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women

Condition: HIV Infections

NCT ID: NCT00592124

Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery

Condition: HIV Infections

NCT ID: NCT00540605

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

Condition: HIV Infections

NCT ID: NCT00608569

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

Condition: HIV-1 Infection

NCT ID: NCT01772940

On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Condition: HIV Infection

NCT ID: NCT01473472

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density

Condition: HIV

NCT ID: NCT01153217

Study of Anti-HIV Therapy Intensification

Condition: HIV Infections

NCT ID: NCT00034086

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Condition: HIV Infections

NCT ID: NCT00525733

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

Condition: HIV-1 Infection

NCT ID: NCT00534352

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00384904

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

Condition: HIV Infections

NCT ID: NCT00648817

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women

Condition: HIV Infections

NCT ID: NCT00625404

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Condition: HIV Infection

NCT ID: NCT01751646

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

Condition: HIV Infections

NCT ID: NCT00729573

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

Condition: HIV Infections

NCT ID: NCT00214890

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Condition: HIV

NCT ID: NCT00931801

Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey

Condition: HIV Infection

NCT ID: NCT01322932

Effect of Tenofovir DF on Bone Metabolism in Children

Condition: HIV Infections

NCT ID: NCT00088309

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

Condition: HIV-1 Infection; Pf Subclinical Parasitemia

NCT ID: NCT01632891

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

Condition: HIV Infections

NCT ID: NCT00273273

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00762892

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Condition: HIV

NCT ID: NCT00757783

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Condition: Human Immunodeficiency Virus

NCT ID: NCT01180075

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study

Condition: HIV Infections

NCT ID: NCT00537966

Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

Condition: HIV-1 Infection

NCT ID: NCT01286740

Study to Evaluate Switching From Regimens Consisting of Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed Dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition: HIV-1 Infection

NCT ID: NCT01252940

Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.

Condition: HIV Infection

NCT ID: NCT00386659

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Condition: HIV-1 Infection

NCT ID: NCT01489046

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients

Condition: HIV

NCT ID: NCT01291459

Safety and Efficacy Study of Switching From Epzicom to Truvada

Condition: HIV Infection

NCT ID: NCT00724711

ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

Condition: HIV Infections

NCT ID: NCT00615745

Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM)

Condition: Amphetamine-Related Disorders; HIV; HIV Infections

NCT ID: NCT00856323

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Condition: HIV Infections

NCT ID: NCT00552240

Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection

Condition: Hepatitis B Virus; HIV Infections

NCT ID: NCT00476463

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Condition: HIV

NCT ID: NCT01214759

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

Condition: Acute HIV Infection

NCT ID: NCT00734344

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

Condition: HIV Prevention

NCT ID: NCT01781806

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men

Condition: HIV Prevention; HIV Infections

NCT ID: NCT01087840

Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women

Condition: HIV Infections

NCT ID: NCT01490671

VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

Condition: Hepatitis C; HCV; HIV; AIDS

NCT ID: NCT00828789

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

Condition: HIV Infections

NCT ID: NCT00089505

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Condition: HIV-1 Infection

NCT ID: NCT01803074

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Condition: HIV Infections

NCT ID: NCT00118898

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

Condition: HIV Infections

NCT ID: NCT00090779

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

Condition: HIV Infections

NCT ID: NCT00369941

Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Condition: HIV Infections

NCT ID: NCT00099632

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Condition: HIV Infections

NCT ID: NCT00272779

Tissue Drug Levels of HIV Medications

Condition: Human Immunodeficiency Virus

NCT ID: NCT01490346

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Condition: HIV Infections; Acquired Immune Deficiency Syndrome

NCT ID: NCT01173510

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Condition: Hepatitis C; HIV Infections

NCT ID: NCT00545558

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Condition: Human Immuno Deficiency (HIV) Infections

NCT ID: NCT00799864

A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

Condition: HIV-1

NCT ID: NCT00824421

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Condition: HIV

NCT ID: NCT01232127

Safety of Raltegravir When Given as Part of HIV Therapy in HIV/HCV Coinfected Individuals

Condition: HIV/ Hepatitis C Co-Infection

NCT ID: NCT01147107

Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Condition: HIV; Dyslipidemia

NCT ID: NCT01458977

Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients

Condition: Hiv Infection With Antiretroviral Therapy Indication; CD4 Below 350/µL or Below 15%

NCT ID: NCT00199979

Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China

Condition: HIV Infections; Central Nervous System Diseases; Dementia

NCT ID: NCT01340950

Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism

Condition: HIV Infections

NCT ID: NCT00759070

A Dose Escalation Study of GS-7340-02 in Treatment Naive Patients

Condition: HIV Infections

NCT ID: NCT00036634

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

Condition: HIV Transmission; HIV Infections

NCT ID: NCT00949234

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Condition: HIV Infections

NCT ID: NCT00084136

Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial

Condition: HIV Infection; Pregnancy; Breastfeeding; HIV Infections

NCT ID: NCT00936195

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

Condition: HIV Infections

NCT ID: NCT00344760

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

Condition: HIV Infections

NCT ID: NCT00036452

Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism

Condition: HIV-Infected Children

NCT ID: NCT01361165

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Condition: HIV Infections

NCT ID: NCT00260078

Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infection

NCT ID: NCT00811954

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

NCT ID: NCT01715636

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

Condition: HIV Infected

NCT ID: NCT01394133

Kaletra and Viread in Antiretroviral Naïve Patients

Condition: HIV Infections

NCT ID: NCT00679926

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Condition: HIV

NCT ID: NCT01602822

PREventing Progression of Adipose Tissue Redistribution

Condition: HIV Infections

NCT ID: NCT00389194

Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation

Condition: Renal Function; HIV Infection

NCT ID: NCT01138241

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Condition: HIV-1 Infection

NCT ID: NCT01400412

Intense Acute Infection Study

Condition: Acute HIV Infection

NCT ID: NCT01154673

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01231555

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Condition: HIV Infections

NCT ID: NCT00365339

FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir

Condition: HIV-1 Infection

NCT ID: NCT01777997

Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP

Condition: HIV; Pregnancy

NCT ID: NCT00204308

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Condition: HIV

NCT ID: NCT01293123

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01102972

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

Condition: HIV Infections

NCT ID: NCT00561496

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

Condition: Primary HIV (Acute or Early); Chronic HIV Infection

NCT ID: NCT00641641

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

Condition: HIV Infections

NCT ID: NCT00885664

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

Condition: HIV Infections

NCT ID: NCT00192634

The Mochudi Prevention Project ART Protocol

Condition: HIV Infections

NCT ID: NCT01583439

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

Condition: HIV Infections

NCT ID: NCT01294761

Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz

Condition: HIV Infections

NCT ID: NCT01160120

"The Once A Day Protease Inhibitor Regimens"

Condition: HIV Infections; Antiretroviral Therapy

NCT ID: NCT00242216

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Condition: Human Immunodeficiency Virus Infection

NCT ID: NCT00711009

Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)

Condition: HIV Infection; Pregnancy

NCT ID: NCT00334256

Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

Condition: HIV

NCT ID: NCT01694017

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Condition: HIV Infections

NCT ID: NCT00414635

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Condition: HIV Infection; Hepatitis C

NCT ID: NCT01285050

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

Condition: HIV Infections

NCT ID: NCT00389402

Safety Study of Once a Day ART and Opiate Substitute.

Condition: HIV Infections

NCT ID: NCT00324688

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Condition: HIV Infections

NCT ID: NCT00050895

Safety and Acceptability of a Vaginal Microbicide

Condition: HIV Infections; Hepatitis B, Chronic

NCT ID: NCT00111943

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Condition: HIV Infections

NCT ID: NCT00046033

Switch to Unboosted Atazanavir With Tenofovir Study

Condition: HIV Infection

NCT ID: NCT01351740

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Condition: HIV Infections; Hepatitis C

NCT ID: NCT00100581

Artery Elasticity After Switch From Epzicom to Truvada

Condition: HIV Infections

NCT ID: NCT00998582

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Condition: HIV Infections

NCT ID: NCT00752856

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Condition: HIV Infections; AIDS-Related Opportunistic Infections

NCT ID: NCT00055120

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

Condition: HIV

NCT ID: NCT00960622

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Condition: HIV Infections

NCT ID: NCT00027339

Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)(COMPLETED)

Condition: HIV Infections

NCT ID: NCT00705419

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

Condition: HIV Infections

NCT ID: NCT00357552

Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+

Condition: HIV Seropositivity

NCT ID: NCT01174914

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

Condition: HIV-1 Infection

NCT ID: NCT01403051

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Condition: HIV Infections; Tuberculosis

NCT ID: NCT00822315

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Condition: HIV

NCT ID: NCT01343225

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Condition: HIV

NCT ID: NCT01270802

Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya

Condition: HIV Infections

NCT ID: NCT00427297

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Condition: HIV-1 Infection

NCT ID: NCT01515813

Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial

Condition: HIV Infections

NCT ID: NCT00643968

Tenofovir Gel in Pregnancy and Lactation

Condition: HIV Infections

NCT ID: NCT01136759

MARCH Central Nervous System Substudy

Condition: HIV-1 Infection

NCT ID: NCT01637233

Drug Drug Interaction of BI 201335 and Tenofovir

Condition: HIV Infections

NCT ID: NCT01340196

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Condition: HIV Infections

NCT ID: NCT01066858

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Condition: HIV Infections

NCT ID: NCT01327651

Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC

Condition: HIV Infections

NCT ID: NCT00338390

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

Condition: HIV Infections; AIDS

NCT ID: NCT00344981

ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment

Condition: HIV

NCT ID: NCT01671982

Sex, Aging and Antiretroviral Pharmacokinetics

Condition: HIV Infections

NCT ID: NCT00666055

Anti-Retrovirals for Kaposi's Sarcoma

Condition: Kaposi's Sarcoma; HIV Infections

NCT ID: NCT00444379

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Condition: HIV; Hepatitis C

NCT ID: NCT01225705

Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.

Condition: HIV

NCT ID: NCT00270556

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT00951015

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Condition: HIV

NCT ID: NCT01620944

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Condition: HIV Infections

NCT ID: NCT00667433

A Key Link for Transmission Prevention

Condition: HIV

NCT ID: NCT01450189

Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

Condition: HIV Infections

NCT ID: NCT00028132

Phase IIB Pilot of Atazanavir + Raltegravir

Condition: HIV

NCT ID: NCT00768989

QoL and Adherence to One-pill Once-a-day HAART

Condition: HIV Infection; HIV Infections

NCT ID: NCT00990600

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Condition: HIV

NCT ID: NCT01003990

ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial

Condition: HIV-1

NCT ID: NCT00772902

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections

NCT ID: NCT00977756

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Condition: HIV Infections

NCT ID: NCT00102206

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Condition: HIV Infections

NCT ID: NCT00323492

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

Condition: HIV-1

NCT ID: NCT01274780

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

Condition: HIV Prevention

NCT ID: NCT01575405

Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection

Condition: Hiv

NCT ID: NCT01751555

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

Condition: Human Immunodeficiency Viruses; Kidney Failure; HIV Infections

NCT ID: NCT00551655

A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients

Condition: HIV

NCT ID: NCT00199121

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics

Condition: HIV Infections

NCT ID: NCT01632995

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

Condition: HIV Infections

NCT ID: NCT01061151

Atripla to Raltegravir Switch Study

Condition: HIV Infection

NCT ID: NCT01195467

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Condition: HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease

NCT ID: NCT00192660

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Condition: HIV Infections

NCT ID: NCT00677300

Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma

Condition: HIV-1 Infection; Kaposi's Sarcoma

NCT ID: NCT01352117

A Study of PMPA in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00002180

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

Condition: HIV Infections

NCT ID: NCT00312169

Pre-Exposure Prophylaxis in YMSM

Condition: HIV

NCT ID: NCT01033942

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00851799

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Condition: Immune Reconstitution Inflammatory Syndrome; HIV; HIV Infections

NCT ID: NCT00988780

Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study

Condition: HIV, Combination Therapy

NCT ID: NCT01332227

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

Condition: HIV; Cardiovascular Disease

NCT ID: NCT01258439

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Condition: Leukoencephalopathy, Progressive Multifocal; HIV Infections

NCT ID: NCT00120367

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE)

Condition: HIV

NCT ID: NCT01253538

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01449929

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Condition: HIV-1 Infection

NCT ID: NCT01352715

Microbicide Safety and Acceptability in Young Men

Condition: High Risk MSM; HIV Negative; 18-30 Years of Age

NCT ID: NCT01283360

Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

Condition: HIV Infections

NCT ID: NCT00428116

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

Condition: HIV-1 Infection

NCT ID: NCT00323687

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Condition: Opioid Dependency; HIV Infections

NCT ID: NCT00877591

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Condition: Acquired Immune Deficiency Syndrome

NCT ID: NCT00775606

Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

Condition: HIV Infections

NCT ID: NCT00820118

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Condition: HIV

NCT ID: NCT01687218

Examining Hair to Determine Tenofovir Exposure

Condition: HIV

NCT ID: NCT00903084

To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir

Condition: HIV

NCT ID: NCT00335192

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Condition: HIV-1 Infection

NCT ID: NCT01641367

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

Condition: HIV

NCT ID: NCT00344461

Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers

Condition: HIV

NCT ID: NCT01796431

Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision

Condition: HIV

NCT ID: NCT01645813

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Condition: HIV

NCT ID: NCT01701882

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

Condition: HIV

NCT ID: NCT01694407

Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection With the Objective to Induce a Strong Specific HIV Immune Response Able to Control Viral Replication Without Highly Active Anti-Retroviral Therapy (HAART)

Condition: HIV

NCT ID: NCT00979706

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Condition: HIV

NCT ID: NCT01778413

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

Condition: HIV

NCT ID: NCT01276600

MARCH Renal Substudy

Condition: Proteinuria; HIV

NCT ID: NCT01637259

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Condition: HIV Infections

NCT ID: NCT00039741

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Condition: HIV Infection

NCT ID: NCT00225082

Intensive Viral Dynamics Substudy of A5248

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00852618

Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)

Condition: HIV Infections

NCT ID: NCT00346567

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Condition: HIV Infection

NCT ID: NCT00931346

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Condition: HIV Infections

NCT ID: NCT00971230

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Condition: HIV Prevention

NCT ID: NCT01421368

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

Condition: HIV Prevention

NCT ID: NCT01575418

A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection

Condition: Infection; HIV

NCT ID: NCT01697046

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Condition: HIV Infection

NCT ID: NCT01772823

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

Condition: HIV Infection

NCT ID: NCT01769456

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

Condition: HIV Prevention

NCT ID: NCT01768962

Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

Condition: HIV Infections; Lipoatrophy

NCT ID: NCT00978237

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Condition: HIV

NCT ID: NCT01255371

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Condition: HIV Infections

NCT ID: NCT00703586

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Condition: HIV

NCT ID: NCT01348763

Single Dose Truvada in HIV-negative Men and Women

Condition: Pharmacokinetic Study in Healthy Volunteers

NCT ID: NCT01326221

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

Condition: HIV Infection

NCT ID: NCT01474954

Post-Exposure Prophylaxis in Health Care Workers

Condition: Human Immunodeficiency Virus

NCT ID: NCT01234116

Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00876733

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

Condition: HIV-1 Infections

NCT ID: NCT00984152

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Condition: Infection, Human Immunodeficiency Virus I

NCT ID: NCT01263015

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Condition: HIV Infection

NCT ID: NCT01380080

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

Condition: HIV-1 Infection

NCT ID: NCT01701895

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Condition: Women's Health; HIV Infection; Genital Diseases, Female

NCT ID: NCT01456962

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

Condition: HIV Infections

NCT ID: NCT00543803

Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection

Condition: HIV Infections; Liver Toxicity; Hepatitis Co-infection

NCT ID: NCT01273142

Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients

Condition: Mitochondrial Toxicity; Metabolic Complications

NCT ID: NCT01601899

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Condition: Tuberculosis

NCT ID: NCT01690403

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc/Lamivudine

Condition: HIV; Impaired Cognition

NCT ID: NCT01367236

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Condition: HIV Infections

NCT ID: NCT00615810

Evaluation of Albuminuria HIV-Infected Patients

Condition: HIV-Associated Focal Segmental Glomerulosclerosis; HIV-Associated Collapsing Glomerulopathy; Proteinuria; Albuminuria; Renal Tubular Toxicity

NCT ID: NCT00524992

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Condition: HIV Infections

NCT ID: NCT01159223

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Condition: HIV-1

NCT ID: NCT01254656

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Condition: Human Immunodeficiency Virus; HIV

NCT ID: NCT01541085

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Condition: HIV Infections; Hepatitis C

NCT ID: NCT01105611

Antiretroviral Therapy for Acute HIV Infection

Condition: Acute HIV Infection

NCT ID: NCT00796263

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Condition: HIV-1

NCT ID: NCT00324649

HIV Viral Load Monitoring in Resource-Poor Settings

Condition: HIV; AIDS; HIV Infections

NCT ID: NCT00929604

Impact of Immediate Versus WHO Recommendations Guided ART Initiation on HIV Incidence - Feasibility Phase

Condition: HIV Infection

NCT ID: NCT01509508

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events

Condition: HIV-Infection

NCT ID: NCT01417949

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

Condition: HIV

NCT ID: NCT01712425

HIV and Kidney Function Study

Condition: HIV Infections; AIDS

NCT ID: NCT00905151

Bone Mineral Density in HIV+ Patients

Condition: Bone Mineral Density; Bone; Osteoporosis

NCT ID: NCT01378494

A Prospective, Observational Study to Examine the Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'

Condition: HIV Positive; Ageing

NCT ID: NCT01737047

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

Condition: HIV Infection

NCT ID: NCT01271894

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Condition: HIV Infection

NCT ID: NCT00280969

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

Condition: HIV Infections; Fanconi Syndrome; Kidney Disease; Renal Impairment

NCT ID: NCT00499187

Safety and Effectiveness of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density

Condition: HIV Infections

NCT ID: NCT00921557

Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)

Condition: HIV; Bone Mineral Density; Bone Turnover; Fracture

NCT ID: NCT01591252

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Condition: HIV-positive Subjects With HIV-RNA <50 Copies/mL

NCT ID: NCT01792570

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Condition: HIV Infections

NCT ID: NCT00144105

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

The Raltegravir 60+ Study

Condition: HIV

NCT ID: NCT01335620

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Condition: Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus

NCT ID: NCT01448707

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Condition: HIV Infections

NCT ID: NCT01632345

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Condition: HIV Infections

NCT ID: NCT00224445

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Condition: Human Immunodeficiency Virus Infections

NCT ID: NCT00262522

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

Condition: HIV Infection; Tuberculosis

NCT ID: NCT00108862

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Condition: HIV

NCT ID: NCT00745823

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Condition: Seizures; Infection, Human Immunodeficiency Virus

NCT ID: NCT01458132

GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance

Condition: HIV Infections

NCT ID: NCT00362687

The First Failure Study

Condition: HIV; HIV Infections

NCT ID: NCT01118871

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

Condition: Stimulant-Related Disorders; HIV; HIV Infections

NCT ID: NCT01140880

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

NCT ID: NCT01366547

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Condition: HIV; HIV Infections

NCT ID: NCT00966329

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01622790

Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.

Condition: HIV Infections

NCT ID: NCT01011413

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

Condition: HIV Infection

NCT ID: NCT01451333

Early HIV Therapy in Patients With High CD4 Cell Counts

Condition: HIV

NCT ID: NCT01479634

Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg

Condition: Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID

NCT ID: NCT00476983

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Condition: HIV Infection; Hyperlipidemia

NCT ID: NCT00225017

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Condition: HIV

NCT ID: NCT01605084

Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue

Condition: Lipodystrophy

NCT ID: NCT00647946

The Neurocognitive Sub-study of Encore1

Condition: HIV

NCT ID: NCT01516060

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

Condition: Prevention

NCT ID: NCT01369303